Garuda - Garba Rujukan Digital

Immunotherapy in Lung Cancer: A Narrative Literature Review Hendris Utama Citra Wahyudin; Afriani Afriani; Fenty Anggrainy; Sabrina Ermayanti
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 1 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i1.755

Lung cancer is the most common cause of death from cancer in both men and women worldwide. Cancers with low immunogenicity often do not present antigens, so immune responses can be avoided. Uncontrolled growth of tumor cells occurs due to various factors such as activation of immunosuppressive mechanisms, induction of various immunosuppressive cells, and expression of immune checkpoint molecules. The development of lung cancer management has progressed since the discovery of molecular-based target therapy and immunotherapy. The high expression of tumor mutational burden in lung cancer indicates high immunogenicity in lung cancer. Various immunological mechanisms involving programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have been developed for the treatment of lung cancer by utilizing immune system modulation. Nivolumab is the first approved immunotherapy for lung cancer, followed by pembrolizumab, atezolizumab, and durvalumab. The use of immunotherapy involving immune checkpoint inhibitors is an important breakthrough in the management of cancer, including lung cancer. This literature review aimed to describe immunotherapy in lung cancer that focuses on immune checkpoint inhibitors anti-PD-1 and anti-PD-L1.

Immunotherapy in Lung Cancer: A Narrative Literature Review Hendris Utama Citra Wahyudin; Afriani Afriani; Fenty Anggrainy; Sabrina Ermayanti
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 1 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i1.755

Lung cancer is the most common cause of death from cancer in both men and women worldwide. Cancers with low immunogenicity often do not present antigens, so immune responses can be avoided. Uncontrolled growth of tumor cells occurs due to various factors such as activation of immunosuppressive mechanisms, induction of various immunosuppressive cells, and expression of immune checkpoint molecules. The development of lung cancer management has progressed since the discovery of molecular-based target therapy and immunotherapy. The high expression of tumor mutational burden in lung cancer indicates high immunogenicity in lung cancer. Various immunological mechanisms involving programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have been developed for the treatment of lung cancer by utilizing immune system modulation. Nivolumab is the first approved immunotherapy for lung cancer, followed by pembrolizumab, atezolizumab, and durvalumab. The use of immunotherapy involving immune checkpoint inhibitors is an important breakthrough in the management of cancer, including lung cancer. This literature review aimed to describe immunotherapy in lung cancer that focuses on immune checkpoint inhibitors anti-PD-1 and anti-PD-L1.

Correlation of the Adverse Event Following Immunization with the Severity of COVID-19 Infection in Health Care Workers in Padang Sabrina Ermayanti; Fenty Anggrainy; Kornelis Aribowo; Muhammad Bagus H.S.; Rizki Amrika; Dwi Rizki Fadhilah
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 7 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i7.837

Background: Effective countermeasures to control the current COVID-19 pandemic are the implementation of health protocols and vaccinations. The problem that must be a concern after vaccination is post-immunization co-occurrence (AEFI), including COVID-19 vaccination. Another issue that is also a concern after vaccination is the incidence of being infected with COVID-19. The purpose of this study was to determine the incidence of post-vaccination COVID-19 infection in health workers in the city of Padang and its association with the incidence of COVID-19 vaccine AEFIs. Methods: The study used a descriptive-analytic design with a retrospective cohort method. The research will be carried out in all hospitals in Padang, and sampling will be carried out for 2 months, from November to December 2021. Officers who are confirmed to have COVID-19 after vaccination and meet the inclusion criteria are healthcare workers who have received at least 2 vaccines and are willing to fill out a Google form. Results: The characteristics of health workers in Padang who were confirmed to have COVID-19 after 2 vaccinations were mostly (68.1%) early adults (26-35 years), the sex was mostly female as much as 77.3%, and most professions were workers. Paramedics (nurses or midwives) as much as 57.0%. The most comorbid obesity is as much as 3.4%. Nutritional status assessed by BMI showed that obesity (37.7%) and normal nutritional status (32.9%) had almost the same proportion. Almost all health workers with or without AEFI experience mild COVID-19, as many as 98%, and experience COVID-19 infection 28 days after vaccination. Conclusion: The incidence of AEFI is not related to the severity of post-vaccination COVID-19 infection in health workers in Padang.

Correlation of the Adverse Event Following Immunization with the Severity of COVID-19 Infection in Health Care Workers in Padang Sabrina Ermayanti; Fenty Anggrainy; Kornelis Aribowo; Muhammad Bagus H.S.; Rizki Amrika; Dwi Rizki Fadhilah
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 7 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i7.837

Background: Effective countermeasures to control the current COVID-19 pandemic are the implementation of health protocols and vaccinations. The problem that must be a concern after vaccination is post-immunization co-occurrence (AEFI), including COVID-19 vaccination. Another issue that is also a concern after vaccination is the incidence of being infected with COVID-19. The purpose of this study was to determine the incidence of post-vaccination COVID-19 infection in health workers in the city of Padang and its association with the incidence of COVID-19 vaccine AEFIs. Methods: The study used a descriptive-analytic design with a retrospective cohort method. The research will be carried out in all hospitals in Padang, and sampling will be carried out for 2 months, from November to December 2021. Officers who are confirmed to have COVID-19 after vaccination and meet the inclusion criteria are healthcare workers who have received at least 2 vaccines and are willing to fill out a Google form. Results: The characteristics of health workers in Padang who were confirmed to have COVID-19 after 2 vaccinations were mostly (68.1%) early adults (26-35 years), the sex was mostly female as much as 77.3%, and most professions were workers. Paramedics (nurses or midwives) as much as 57.0%. The most comorbid obesity is as much as 3.4%. Nutritional status assessed by BMI showed that obesity (37.7%) and normal nutritional status (32.9%) had almost the same proportion. Almost all health workers with or without AEFI experience mild COVID-19, as many as 98%, and experience COVID-19 infection 28 days after vaccination. Conclusion: The incidence of AEFI is not related to the severity of post-vaccination COVID-19 infection in health workers in Padang.

The Effect of Dexamethasone on IL-6 Levels in Confirmed COVID-19 Patients Treated at RSUP Dr. M. Djamil Padang Bobby Hasibuan; Irvan Medison; Fenty Anggrainy
Jurnal Respirologi Indonesia Vol 43, No 3 (2023)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v43i3.426

Background: Elevated IL-6 levels have been found in COVID-19 patients and are associated with a poor prognosis. According to COVID-19 management guidelines, several types of corticosteroids can be used as therapy modalities for COVID-19 patients, including dexamethasone, methylprednisolone, and hydrocortisone. The purpose of this study was to examine how dexamethasone administration affected changes in IL-6 levels in confirmed COVID-19 patients at RSUP Dr. M. Djamil Padang.Methods: This was a retrospective cohort study with a sample of all COVID-19 patients who met the inclusion and exclusion criteria and were treated in the COVID-19 isolation ward at RSUP Dr. M. Djamil Padang. The study began in June 2021 and concluded in July 2022. The data was analyzed both descriptively and analytically. The distribution of frequencies and proportions of each variable was included in the univariate analysis. Bivariate analysis employs data-scale-appropriate statistical tests such as the T-test to determine the relationship between independent and dependent variables.Results: The characteristic of the patients were mostly 18-49 years old (37.22%), female (55.67%), of severe clinical degree (49.44%), had no comorbidities (52.78%) and the majority (77.78%) received dexamethasone in the recommended dose (1 x 6 mg). The study's findings revealed that there was no difference in IL-6 values before and after dexamethasone administration in patients with moderate clinical degrees, but there were differences in IL-6 values before and after dexamethasone administration in patients with severe and critical clinical degrees.Conclusion: The IL-6 level has significantly decreased following dexamethasone administration. Dexamethasone administration causes significant changes in IL-6 values in severe and critical degrees but not in moderate clinical degree.

Hubungan Komorbid dengan Outcome Pasien Terkonfirmasi COVID-19 Di RSUP M. Djamil Padang Tahun 2020 Adiiba Turfha Zahira; Ida Rahmah Burhan; Yusticia Katar; Yuniar Lestari; Fenty Anggrainy; Fathiyyatul Khaira
Majalah Kedokteran Andalas Vol 46, No 10 (2024): Supplementary April 2024
Publisher : Faculty of Medicine, Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25077/mka.v46.i10.p1592-1600.2024

Tujuan : Penelitian bertujuan Untuk mengetahui hubungan komorbid dengan outcome pasien terkonfirmasi COVID-19 di RSUP. M. Djamil Padang tahun 2020. Metode : Penelitian bersifat analitik observasional dengan pendekatan cross sectional. Data dikumpulkan dan diolah dengan menggunakan teknik total sampling , yaitu semua pasien terkonfirmasi COVID-19 yang dirawat di RSUP M.Djamil Padang berdasarkan kriteria inklusi dan ekslusi . Jumlah sampel penelitian sebanyak 468 pasien terkonfimasi COVID-19 yang dirawat pada periode Maret – Desember 2020. Analisis yang digunakan adalah analisis bivariat berupa Chi-Square . Hasil: Hasil penelitian menunjukkan terdapat hubungan yang signifikan antara komorbid dengan outcome pada pasien terkonfirmasi COVID-19 (p=0,010) di RSUP. M.Djamil Padang. Kesimpulan : Berdasarkan hasil penelitian dapat diartikan bahwa terdapat hubungan antara komorbid dengan outcome pada pasien terkonfirmasi COVID-19.

Title

Found 16 Documents
Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title Search

Found 16 Documents Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title

Found 16 Documents
Search